{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:50:56Z","timestamp":1772121056388,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology Plus"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jcvp.2021.100028","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T01:36:32Z","timestamp":1623634592000},"page":"100028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland"],"prefix":"10.1016","volume":"1","author":[{"given":"Lindsay","family":"McDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Wise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frauke","family":"Muecksch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Poston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Mavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Templeton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Furrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaqueline","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Malloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norah","family":"Palmateer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodora","family":"Hatziioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bieniasz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Jenks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcvp.2021.100028_bib0001","unstructured":"The Scottish Government. Coronavirus (COVID-19): Scotland's testing strategy - adapting to the pandemic. 2020. Available at: https:\/\/www.ibms.org\/resources\/documents\/coronavirus-covid-19-scotlands-testing-strategy-adapting-to-the\/. Accessed 6 January 2021."},{"key":"10.1016\/j.jcvp.2021.100028_bib0002","article-title":"SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis","author":"Rostami","year":"2020","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.jcvp.2021.100028_bib0003","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijid.2020.10.011","article-title":"Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: an up-to-date review","volume":"101","author":"Lai","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.jcvp.2021.100028_bib0004","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/infdis\/jiaa523","article-title":"Rodr\u00edguez-Barraquer I. are seroprevalence estimates for severe acute respiratory syndrome coronavirus 2 biased?","volume":"222","author":"Takahashi","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcvp.2021.100028_bib0005","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e338","article-title":"Letter to the Editor: the interpretation of COVID-19 Sero-prevalence study should be cautious","volume":"35","author":"Lee","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.jcvp.2021.100028_bib0006","article-title":"Potential drawbacks of SARS-COV-2 sero-prevalence surveys","author":"Lippi","year":"2020","journal-title":"J. Hosp. Infect."},{"key":"10.1016\/j.jcvp.2021.100028_bib0007","unstructured":"SARS-CoV-2 diagnostic pipeline. FIND. Available at: https:\/\/www.finddx.org\/covid-19\/pipeline\/. Accessed 6 January 2021."},{"key":"10.1016\/j.jcvp.2021.100028_bib0008","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/v4061011","article-title":"Mechanisms of coronavirus cell entry mediated by the viral spike protein","volume":"4","author":"Belouzard","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.jcvp.2021.100028_bib0009","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12967-020-02392-y","article-title":"SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines","volume":"18","author":"Salvatori","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jcvp.2021.100028_bib0010","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201181","article-title":"Measuring SARS-CoV-2 neutralizing antibody activity using pseudo-typed and chimeric viruses","volume":"217","author":"Schmidt","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jcvp.2021.100028_bib0011","article-title":"Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents","author":"Muecksch","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcvp.2021.100028_bib0012","article-title":"Enhanced Surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic","author":"Dickson","year":"2020","journal-title":"Public Health"},{"key":"10.1016\/j.jcvp.2021.100028_bib0013","series-title":"COVID-19 in Children: An Ample Review","first-page":"661","author":"Ciuca","year":"2020"},{"key":"10.1016\/j.jcvp.2021.100028_bib0014","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/archdischild-2020-320042","article-title":"COVID-19 in children: analysis of the first pandemic peak in England","volume":"105","author":"Ladhani","year":"2020","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.jcvp.2021.100028_bib0015","unstructured":"NHS Scotland. Health innovation assessment portal - new evaluations testing Workstream. Available at: http:\/\/www.hiap-scotland.org\/News\/PresentationCategory\/9. Accessed 6 January 2021."},{"key":"10.1016\/j.jcvp.2021.100028_bib0016","doi-asserted-by":"crossref","unstructured":"Poston D, Weisblum Y, Wise H, et\u00a0al. Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection. medRxiv 2020; Available at: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7553167\/. Accessed 17 February 2021.","DOI":"10.1101\/2020.10.08.20209650"},{"key":"10.1016\/j.jcvp.2021.100028_bib0017","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(20)31483-5","article-title":"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based sero-epidemiological study","volume":"396","author":"Poll\u00e1n","year":"2020","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.jcvp.2021.100028_bib0018","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(20)31304-0","article-title":"Sero-prevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study","volume":"396","author":"Stringhini","year":"2020","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.jcvp.2021.100028_bib0019","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.15585\/mmwr.mm6932a4","article-title":"Notes from the field: sero-prevalence estimates of SARS-CoV-2 infection in convenience sample - Oregon, May 11-June 15, 2020","volume":"69","author":"Sutton","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.jcvp.2021.100028_bib0020","article-title":"Sero-prevalence of antibodies to SARS-CoV-2 in six sites in the United States, March 23-May 3, 2020","author":"Havers","year":"2020","journal-title":"Infect. Dis. (except HIV\/AIDS)"},{"key":"10.1016\/j.jcvp.2021.100028_bib0021","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-020-0962-9","article-title":"Age-dependent effects in the transmission and control of COVID-19 epidemics","volume":"26","author":"Davies","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.jcvp.2021.100028_bib0022","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1126\/science.abb8001","article-title":"Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jcvp.2021.100028_bib0023","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jmii.2020.02.011","article-title":"Are children less susceptible to COVID-19?","volume":"53","author":"Lee","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.jcvp.2021.100028_bib0025","doi-asserted-by":"crossref","first-page":"m4944","DOI":"10.1136\/bmj.m4944","article-title":"Covid-19: What have we learnt about the new variant in the UK?","volume":"371","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jcvp.2021.100028_bib0026","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S1473-3099(20)30634-4","article-title":"Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison","volume":"20","author":"Ainsworth","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jcvp.2021.100028_bib0027","article-title":"Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection","author":"Anderson","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.jcvp.2021.100028_bib0028","article-title":"Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels","author":"Harvala","year":"2020","journal-title":"Transfus. Med. Oxf. Engl."},{"key":"10.1016\/j.jcvp.2021.100028_bib0029","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.28.2001260","article-title":"Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020","author":"Harvala","year":"2020","journal-title":"Euro. Surv."},{"key":"10.1016\/j.jcvp.2021.100028_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2020.07.038","article-title":"Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs","volume":"26","author":"Van Elslande","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jcvp.2021.100028_bib0031","article-title":"Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications","author":"Wu","year":"2020","journal-title":"Infect. Dis. (except HIV\/AIDS)"},{"key":"10.1016\/j.jcvp.2021.100028_bib0032","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"}],"container-title":["Journal of Clinical Virology Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266703802100020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266703802100020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:18:30Z","timestamp":1763021910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266703802100020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S266703802100020X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcvp.2021.100028","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.20.21255596","asserted-by":"object"}]},"ISSN":["2667-0380"],"issn-type":[{"value":"2667-0380","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcvp.2021.100028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100028"}}